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Abstract
This paper analyses a large, longitudinal database on inter-ﬁrm R&D partnerships formed in the high-tech pharmaceutical
biotechnology industry since 1975. Our research indicates an overall growth in the number of annually, newly established R&D
partnerships where research partners consistently prefer contractual partnerships to equity-based alliances. In the networks that
develop through these R&D partnerships, small, entrepreneurial biotechnological companies take a leading role during the 1980s
when biotechnology ﬁrst became relevant for the pharmaceutical industry. The 1990s, however, show a different pattern with
established, large pharmaceutical companies becoming more dominant, acting as nodal players with multiple partnerships with a
variety of other companies.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
The main purpose of this paper is to present an
overview of major long-term trends and patterns in
R&D partnering between companies that operate in the
high-techpharmaceuticalbiotechnologyindustry.Inthat
context, we study pharmaceutical biotechnology R&D
partnerships formed by all companies active in pharma-
ceuticalbiotechnology,apopulationthatconsistsmainly
oflargepharmaceuticalcompanies,diversiﬁedchemical
companies, and a range of dedicated biotech companies.
The starting point for this analysis is the mid-1970s,
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when pharmaceutical biotechnology was still at its very
early stage of both technological and commercial devel-
opment. We will follow the development of this emerg-
ing sector of industry until the end of the 1990s. The
main data source for our analysis is the MERIT-CATI
database (see Appendix A).
After we present an overview of general trends in
R&D partnerships, which demonstrates a somewhat
cyclical growth pattern in the number of newly estab-
lished partnerships, we will discuss some interesting
features of major modes of research cooperation
between companies. Traditionally, high-tech companies
have preferred to use equity joint ventures as a major
mode of cooperation, but gradually they have started
to experiment with other forms of cooperation. For
pharmaceutical biotechnology, we will look at some
trends in the choice that companies make with regard
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to several modes of research cooperation, such as R&D
joint ventures, minority holdings, R&D agreements,
and research contracts.
In the next section, we will discuss some major
changes in the structure of research partnering networks
over time, examining both network-level characteristics
and partnering behavior at the level of individual ﬁrms.
This part of the analysis ﬁrst concentrates on the rep-
resentation of actual inter-ﬁrm R&D networks formed
during ﬁve periods of 5 years, beginning with the period
1975–1979 and ending with the period 1995–1999.
It presents an intriguing story of networks that are
gradually becoming more and more complex, starting
as isolated pairs of cooperating companies with a few
small clusters of multi-partner networks developing
into a very dense, interrelated, large network with a
multitude of companies. When we analyze the role
played by individual companies, we will concentrate
on both large, established pharmaceutical companies
and relatively small, entrepreneurial biotechnology
ﬁrms that are known for having played a crucial role
in the development of pharmaceutical biotechnology
(see e.g. Arora and Gambardella, 1990; Barley et al.,
1992; Pisano, 1991; Powell et al., 1996; Roijakkers et
al., 2005). Our analysis will get a clear Schumpeterian
ﬂavor when we examine the role of both groups of
companies and their individual ‘representatives’ in
the changing networks of inter-ﬁrm R&D partnering
throughout the sub-periods that we study.
In the ﬁnal section, we will draw some conclusions
regarding the main topics of this paper. A number of
appendices describe our data and data sources and our
own network visualization software tool.
2. General trends in R&D partnerships since
1975
2.1. Historical growth pattern
Previous research (see amongst others Chesnais,
1988; Hagedoorn, 2002; Hergert and Morris, 1988;
Hladik, 1985; Mariti and Smiley, 1983; OECD, 1986,
1992) has established that, after a small growth in
the number of inter-ﬁrm partnerships made during the
1970s, the formation of these partnerships did not really
takeoffuntilthebeginningofthe1980s.Wealsoﬁndthis
particular growth pattern for the group of partnerships
studied in this paper, i.e. pharmaceutical biotechnology
R&D partnerships. Fig. 1 shows the particular trend in
the formation of newly established R&D partnerships in
pharmaceutical biotechnology as well as the growth in
overall partnering activity during the period 1975–1999.
During the second half of the 1970s, the number of
newly established pharmaceutical biotechnology R&D
partnerships, as found in the MERIT-CATI database,
remainedataverylowlevelofbetweenafewtoabout10
partnerships made each year during most of that period.
Fig. 1 also indicates that R&D partnerships formed
by companies active in pharmaceutical biotechnology
account for a very small share of the total number of
partnerships (less than 6%) made during the last couple
of years of the 1970s.
Fig. 1. Growth of numbers of newly established R&D partnerships in general and in pharmaceutical biotechnology, 1975–1999; source: MERIT-
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During the ﬁrst half of the 1980s, there is a grad-
ual increase of the number of newly established R&D
partnershipsfromfewerthan20pharmaceuticalbiotech-
nology partnerships in 1980 to about 40 agreements in
1984. This particular growth pattern continues well into
the second half of the 1980s, ultimately reaching a high
level of around 65 partnerships made in 1986. The last
couple of years of the 1980s show a substantial drop in
the newly established R&D partnerships to slightly over
30pharmaceuticalbiotechnologyalliancesin1989.Ifwe
examine the overall trend in the total number of newly
established R&D partnerships formed during the 1980s,
it is obvious that this number increases more rapidly
than the number of newly established pharmaceutical
biotechnology partnerships. In relative terms, the share
ofbiotechnologicalpartnershipsintotalallianceactivity
hasincreasedsomewhattomorethan10%ofallalliances
in the late 1980s (see Fig. 1).
During the early 1990s, the number of newly estab-
lished pharmaceutical biotechnology alliances drops
even further to fewer than 20 R&D partnerships in 1990
after which this number takes off again to reach a high
level of about 170 partnerships in 1996. At the end of
the period of our analysis, the number of newly estab-
lished partnerships is decreasing again to slightly over
100 alliances in 1998. The observed increase in biotech-
nological R&D partnerships to more than 140 newly
established agreements in 1999 could signal the begin-
ning of another period of growth of these alliances (see
Fig. 1). At this point, it is also important to mention that,
from 1994 onwards, the number of newly established
pharmaceutical biotechnology partnerships maintains a
relatively large, steady share of more than 20% of the
total number of partnerships.
All in all, the historical data on inter-ﬁrm R&D part-
nering in the pharmaceutical biotechnology industry,
reveal, despite some irregularities, an overall growth
patterninthenumberofnewlyestablishedR&Dpartner-
ships since the mid-1970s. During the ﬁnal years of the
1970s, we observe a very modest growth pattern while
the1980sandparticularlythe1990sshowanaccelerated
growth trend with clear peaks in 1986 and 1996 as well
as a signiﬁcant drop in alliance activity in 1990. This,
seemingly cyclical, growth pattern is quite identical to
the pattern found for other sectors of industry (see Fig. 1
andalsoHagedoornandvanKranenburg,2003,forasta-
tistical analysis of cyclical patterns in R&D partnering).
A plausible explanation for the particular pattern in
the newly established biotechnological R&D alliances,
found in the CATI database, is related to the instabil-
ity of capital markets in the ﬁnal years of the 1980s. In
the ﬁrst half of the 1980s, venture capital ﬁrms invested
largesumsofmoneyinresource-intensiveR&Dprojects
undertaken by small, newly founded biotechnological
companies(Hakanssonetal.,1993;Senker,1996;Walsh
et al., 1995). Originally based on academic research
that led to important technological changes, most of
the biotechnology ﬁrms were founded to commercially
exploit promising new technologies, such as genetic
engineering and cell fusion. Unable as yet to produce
their own working capital, nearly all of the start-ups
were highly dependent on venture capitalists as the sin-
gle largest source of their funds.
After the stock market collapse of 1987, how-
ever,venturecapitalistsbecameincreasinglypessimistic
about the commercialization potential of biotechnology
and their interest to invest in biotechnology ﬁrms began
to wane (Barley et al., 1992; Galambos and Sturchio,
1998). The rapidly decreasing availability of venture
capital during the second half of the 1980s caused
an initial shakeout in the industry with large numbers
of biotechnology companies ﬁling for bankruptcy. The
lowernumberofpossiblebiotechnologicalresearchpart-
nersavailabletopharmaceuticalcompaniesmayprovide
a tentative explanation for the substantial decrease in
the number of newly established R&D partnerships dur-
ing the last couple of years of the 1980s. It was also
during these years that the main source of ﬁnance for
biotechnology companies shifted from venture capital
ﬁrms to pharmaceutical companies, which shows up in
thegrowthofnewlyestablishedpharmaceuticalbiotech-
nology partnerships during the 1990s (see also Barley et
al., 1992; Senker and Sharp, 1997).
Besides this shift in the sources of investment cap-
ital, this recent upsurge in R&D alliances can also
be explained by the rapid increase in biotechnologi-
cal knowledge and the rise of a broad range of new
technologicalareastriggeredbyinﬂuential,government-
sponsored research programs, such as the US-based
Human Genome Project (Orsenigo et al., 2001; Santos,
2003). As a result of these developments, pharmaceu-
tical companies and biotechnology ﬁrms increasingly
engaged in alliances with others in order to carry out
exploratory research across this broad range of techni-
cal areas and take advantage of the many commercial
opportunities that were opening up in these ﬁelds.
2.2. Modes of cooperation
At this point, it is important to mention that
established pharmaceutical ﬁrms and small, newly
founded biotechnology companies typically cooperate
on research through a speciﬁc number of organizational
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agreements, such as research joint ventures and minor-
ity holdings, and a number of contractual modes, such
as joint R&D agreements and R&D contracts. Before
examining the speciﬁc trend in the employment of these
different modes of collaboration over time, we ﬁrst dis-
cuss each of these organizational arrangements some-
what further.
Of all types of inter-ﬁrm cooperation, joint ventures
are probably the oldest and most widely studied form of
partnering(Bergetal.,1982;Hladik,1985).Inaresearch
joint venture, two or more separate parent companies
agreetoconductlong-term,sharedR&Dwithinadistinct
organizational entity or ’company’ that is characterized
by common equity ownership. Such equity-based joint
venturestypicallyservethepurposeofsubstantiallylow-
ering the costs of transaction between the independent
research partners. More speciﬁcally, partners to a joint
venture are not very likely to behave in an opportunistic
manner as this kind of behavior leads the whole venture
to suffer and equity to diminish for the partners involved
(Buckley and Casson, 1988). Minority holdings are
another type of equity-based R&D partnerships where
one research partner obtains a small interest (substan-
tially less than 50%) in another company. These kinds
of arrangements are typically coupled with technology
exchange agreements, giving partners the opportunity to
explore promising new technologies without allocating
large amounts of resources to internal research.
Contractual modes of inter-ﬁrm R&D partnering, in
particular joint R&D agreements, constitute an impor-
tant alternative to equity-based forms of cooperation.
An advantage of contractual partnerships over equity
alliances is that the former group of partnerships pro-
vides research partners with a high degree of ﬂexibility
and enables them to switch from research in one tech-
nological ﬁeld to another (Barley et al., 1992; Obleros
and MacDonald, 1988). Joint R&D agreements involve
the pooling of funds by two or more partners for the
purpose of sharing technological know-how and setting
up joint research and development programs. Research
contracts are examples of contractual partnerships that
regulate R&D cooperation where one partner, typically
a large ﬁrm, contracts another, usually a small, partner
to develop a speciﬁc technology.
Relevantresearchindicatesthattheabsolutenumbers
of contractual, non-equity R&D partnerships as well as
their share in the total number of partnerships far exceed





mation technology and pharmaceuticals, high costs of
R&D and short technology cycles imply that most com-
paniesareunabletostaycurrentwithrespecttothelatest
technological developments solely by relying on their
internal research. By engaging in a portfolio of ﬂexible,
contract-basedresearchpartnerships,high-techﬁrmsare
able to monitor the development of several technologies
atoncewhiletheycanconcentratetheirinternalresearch
efforts on a few, most promising, development projects.
The particular trend for the proportion of contractual
modes in all newly established pharmaceutical biotech-
nologyR&Dpartnerships(seeFig.2)isindicativeofthe
Fig. 2. The share (%) of all contractual modes and joint R&D agreements in all newly established pharmaceutical biotechnology R&D partnerships,
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high importance of contractual arrangements relative to
equity-sharing partnerships, which coincides with ﬁnd-
ings presented in earlier contributions to the analysis
of R&D cooperation in pharmaceutical biotechnology.
During the second half of the 1970s, when a handful of
established pharmaceutical ﬁrms such as Bristol-Myers,
Eli Lilly, and Johnson & Johnson began to explore
new developments in biotechnology, these companies
also engaged in a number of research partnerships with
biotechnological start-ups in order to gain access to new
knowledge. As shown in Fig. 2, more than 80% of these
R&D partnerships, formed during the late 1970s, are
of the contractual type. Apart from a small drop in
1982, the 1980s as well as the 1990s witnessed a steady
increase in the share of contractual arrangements from
more than 80% during most of the 1980s to over 90%
during the ﬁnal years of the 1990s. If we take a look at
the speciﬁc pattern for the share of joint R&D agree-
ments in all newly established partnerships (see also
Fig.2),itappearsthatduringthesecondhalfofthe1970s
and the ﬁrst half of the 1980s, research contracts were
the most popular mode of research interaction. From
1985onwards,companiesincreasinglypreferjointR&D
agreements over R&D contracts. This ﬁnding seems
to indicate two major developments. First, it indicates
the internalization of new biotechnological know-how
by established pharmaceutical ﬁrms that have estab-
lishedtheirownresearchcenters,whichmakesthemless
dependent on the research of specialized ﬁrms. Second,
inter-ﬁrm R&D partnering in pharmaceutical biotech-
nology is more and more characterized by collaboration
of research departments through joint R&D agreements
whereoutsourcingofR&Ditselfhasbecomelessimpor-
tant.
3. The structure of inter-ﬁrm R&D networks
3.1. Network evolution
In the previous section, we identiﬁed and described a
number of important basic developments in biotechno-
logical R&D partnering since the rise of biotechnology
in the early 1970s. We now turn to an overview of major
changes in the structure of research partnering networks
over time, examining both network-level characteristics
and partnering behavior at the level of individual ﬁrms.
Figs. 3–7 give us a graphical representation of
R&Dpartnershipsinpharmaceuticalbiotechnologydur-
ing the periods 1975–1979, 1980–1984, 1985–1989,
1990–1994,1995–1999,usinganon-metricmultidimen-
sionalscaling(MDS)technique.MDSisadatareduction
procedure somewhat comparable to principal compo-
nent analysis and other factor-analytical methods. One
of the main advantages of MDS is that it can usually,
but not necessarily, ﬁt an appropriate model in a two-
dimensional picture. Particularly, MDS offers a scaling
of similarity data into points lying in an X-dimensional
space. The purpose of this method is to provide coor-
dinates for these points in such a way that distances
between pairs of points ﬁt as closely as possible to the
observed similarities. In order to facilitate interpreta-
tion, the solution is given in two dimensions, provided
that the ﬁt of the model is acceptable. A stress value
indicates the goodness-of-ﬁt of the conﬁguration as this
measurestheproportionofthevarianceofthedisparities
that is accounted for by the MDS model, implying that
lower values indicate a better goodness-of-ﬁt (Hair et
al., 1998). For all MDS solutions presented in this paper
Kruskal’s stress values (Kruskal and Wish, 1978) range
from good, e.g. 0.034 for the period 1985–1989, to very
good, e.g. 0.001 for the period 1975–1979.
Using our own network visualization software tool
Najojo(seeAppendixB),weenhancetheinterpretability
of these MDS pictures, ﬁrst, by adding company labels
to the dots, and, second, by drawing lines of different
styles and thickness between pairs of ﬁrms with varying
degrees of partnering intensity. Dotted lines represent
oneR&Dpartnershipbetweencompanies,whereassolid
linesindicatetwoorthreepartnerships.Thicksolidlines
indicate four or more alliances.
During the period 1975–1979, most of the estab-




rative behavior of incumbents clearly show up in the
overallcharacteristicsoftheinter-ﬁrmnetworkthatcame
into existence during these years. Speciﬁcally, the MDS
solution for the period 1975–1979 (see Fig. 3) presents
an extremely sparse, disconnected R&D network that
involves a mere 30 companies where the vast majority
ofthesecompaniesarecooperatingwithinthecontextof
small, biotechnological research clusters. Many clusters
are organized around four or ﬁve research partners at
the most. We also observe quite a few one-on-one part-
nerships between companies that are not part of any of
these clusters, which is also illustrative of the very small
number of partnerships that make up the network for
this period. Also, the majority of ﬁrms are connected to
one speciﬁc research partner through no more than one
alliance.
Turning to the next period, 1980–1984, we observe
a slightly different pattern (see Fig. 4). In the previ-











































































































































































Fig. 5. Inter-ﬁrm R&D partnerships amongst cooperating companies in pharmaceutical biotechnology, 1985–1989; source: MERIT-CATI.N. Roijakkers, J. Hagedoorn / Research Policy 35 (2006) 431–446 439

























































Fig. 7. Inter-ﬁrm R&D partnerships amongst cooperating companies in pharmaceutical biotechnology, 1995–1999; source: MERIT-CATI.N. Roijakkers, J. Hagedoorn / Research Policy 35 (2006) 431–446 441
biotechnology began to take off in the early 1980s and
thisstronggrowthtrendclearlycharacterizestheincreas-
ingly dense research networks of the eighties. Speciﬁ-
cally, the MDS plot for the ﬁrst half of the 1980s shows
a relatively dense research network where the multitude
of lines connects virtually all the partners participating
inthenetwork,eitherdirectlyorindirectly.Interestingly,
the left-hand side of Fig. 4 presents a part of the network
that is somewhat dense because of the sheer number of
partnerships between ﬁrms. By contrast, the right-hand
side of the ﬁgure shows a fairly concentrated area of the
networkthatisdensebecauseoflargenumbersoflonger-
term, repeated ties between pairs of companies. While
the overall R&D network, which is for the most part
basedonresearchcontracts,isrelativelywell-connected,
we also observe a small number of one-on-one ties and
someisolatedresearchclustersatthetopleft-handsideof
Fig. 4.
The total number of inter-ﬁrm R&D partnerships
and, consequently, the R&D network density in the
pharmaceutical biotechnology sector shows a substan-
tial increase if one compares the period 1985–1989 (see
Fig. 5) with the previous one. During these years, com-
mon research efforts and many, newly established joint
R&Dagreementsbetweenestablished,largepharmaceu-
tical ﬁrms and newly founded biotechnological compa-
nies resulted in a much denser, well-connected network
structurewherecooperationismainlyconcentratedatthe
right-hand side of Fig. 5. Nearly all ﬁrms in this dense
research network are either directly or indirectly con-
nected to each other: we observe only a small number
of one-on-one links in the center of the network. Also,
the number of ﬁrms that are connected to one speciﬁc
research partner through at least two R&D alliances has
increased,whichisillustrativefortheincreaseofthetotal
number of R&D partnerships during the second half of
the 1980s.
Although Fig. 1 demonstrates a substantial drop in
the formation of pharmaceutical biotechnology R&D
partnerships in the ﬁrst years of the 1990s, the MDS
solution for the period 1990–1994 (see Fig. 6) shows a
fairly dense, highly connected research network where
more than 300 ﬁrms have engaged in a multitude of
joint R&D agreements. Particularly the top of Fig. 6
illustrates a very dense part of the particular network
that was in existence during the ﬁrst half of the 1990s.
While the majority of companies making up the net-
work for this period are connected to most other ﬁrms
throughtheirmanypartnerships,wealsoobserveaniso-
lated R&D cluster at the right-hand side of Fig. 6. This
small group of ﬁrms, consisting mainly of Chinese com-
panies, is conducting joint biotechnological research at
an isolated network position that seems completely dis-
connected from knowledge generated outside this small
cluster.Furthermore,throughoutthenetworkweobserve
a relatively large number of unique pairs of companies
that are cooperating amongst themselves, but are not
linked to any of the other network participants. With the
exceptionofasmallnumberofstarplayers(alsoshowing
up in Table 1) that have entered into multiple R&D part-
Table 1
A comparison of the top 10 ﬁrms with the most R&D partnerships in pharmaceutical biotechnology in 1975–1979, 1980–1984, 1985–1989,
1990–1994, and 1995–1999 (numbers in brackets)
1975–1979 1980–1984 1985–1989 1990–1994 1995–1999
1 Ciba-Geigy (4) Genentech (14) Chiron (12) Ciba-Geigy (18) Roche (41)
2 Marion Laboratories
(3)
Biogen (10) Biogen (12) Merck (15) SmithKline Beecham
(28)
3 Procordia Nova (3) Genetic Systems (9) SmithKline Beckman
(11)
Glaxo (14) Pﬁzer (23)
4 Genentech (3) Genex (8) Eastman Kodak (11) Eli Lilly (14) Bristol-Myers Squibb
(23)
5 Genex (2) Johnson & Johnson
(8)
Genentech (11) Chiron (13) Rhˆ one-Poulenc (22)
6 Sandoz (2) Amgen (6) Johnson & Johnson (10) SmithKline Beecham
(13)
Glaxo Wellcome (22)





8 Johnson & Johnson
(1)
Mitsui (6) Celltech (9) Eastman Kodak (8) Hoechst (17)
9 Bayer (1) Cetus (6) Genetics Institute (9) Hoechst (8) Bayer (15)
10 Baxter-Travenol Lab-
oratories (1)
Ciba-Geigy (5) Du Pont de Nemours (9) Rhˆ one-Poulenc (7) Warner-Lambert (15)
Source: MERIT-CATI databank.442 N. Roijakkers, J. Hagedoorn / Research Policy 35 (2006) 431–446
nerships with one single research partner, Fig. 6 shows
relatively few solid lines.
In correspondence with the large numbers of newly
established R&D partnerships during the second half of
the 1990s (see Fig. 1), the MDS plot in Fig. 7 shows
a very large, extremely dense R&D network involving
around 600 research partners that are nearly all con-
nected to each other by the numerous direct and indirect
ties.Theresearchnetworkisparticularlyconcentratedat
the right-hand side of the ﬁgure where a small number
of star players form the center of dense research clusters
that are characterized by a large number of participating
companies and quite a few repeated, longer-term part-
nerships between these companies and the star player.
In general, we ﬁnd a fairly large number of tightly con-
nected couples of partnering ﬁrms that have engaged
in two or more common R&D partnerships during the
period 1995–1999. Despite this relatively high number
of repeated ties and the generally high level of network
connection, we also observe nearly ﬁfty unique pairs
of companies that only cooperate amongst themselves
and are thus isolated from the research network and its
knowledge ﬂows.
3.2. Major players
In the above, we provided insight into the structural
development of pharmaceutical biotechnology R&D
networks over time by examining research collaboration
at the level of general networks. Besides this aggregate
level, it is useful to study research networks at the level
of individual ﬁrms and evaluate the importance of par-
ticular network participants for the overall structure of
the networks. For a ﬁrst impression of the role played
by established, large pharmaceutical ﬁrms and newly
founded biotechnological companies in research net-
works,werefertoTable1.Thistableliststhetenleading
network participants with most R&D partnerships in the
biotechnology industry during the periods 1975–1979,
1980–1984, 1985–1989, 1990–1994, and 1995–1999.
Our understanding of the role played by established,
large pharmaceutical ﬁrms and new biotechnological
companies in research networks can be clearly placed
within the Schumpeterian tradition. The importance of
thenewlyfounded,entrepreneurialﬁrmasamajorgener-
ator of innovations is most clearly stressed in the ‘early’
Schumpeter (1934). In this early work, entrepreneurial
companies are small, independent ﬁrms that act as
major agents of change within new industries. These
entrepreneurial companies are innovators that success-
fullyintroducenewproductsofwhichthedevelopmentis
expected to be largely ﬁnanced through external sources
and not so much through internal ﬁnancial resources
(cash-ﬂow).
Many elements of such Schumpeterian entre-
preneurial ﬁrms are clearly present in pharmaceutical
biotechnology.1 In fact both Kenney (1986) and Powell
et al. (1996) depict new biotechnological companies
as an ideal type of modern entrepreneurial ﬁrms. As
mentioned by Arora and Gambardella (1990), Barley
et al. (1992), Pisano (1991), Powell et al. (1996), small,
newly founded biotechnological ﬁrms are frequently
ﬁnanced through venture capital or loans and equity
participation of established pharmaceutical companies.
Originally based on university research, that led to
major scientiﬁc and technological changes, nearly all of
the small, biotechnology companies also started as new
entrants to the pharmaceutical industry (Kenney, 1986;
Pisano, 1990; Powell, 1996).
In terms of their organizational setting and their
organizational culture, most of the new biotechnolog-
ical companies are quite different from the ‘standard’
company that one ﬁnds in traditional industries. New
biotechnological ﬁrms seem to be driven by scientiﬁc
discoveries and innovative performance and not only
by regular proﬁt-seeking (Lumerman Oliver and Porter
Liebeskind, 1997). Also, the ‘academic culture’ within
these innovation-driven and loosely organized compa-
nies, with their informal, non-hierarchical structures,
sets them apart from many other ‘traditional’ companies
(Pisano, 1991; Powell, 1996).
If we look at the role of established ﬁrms in
Schumpeter, we have to understand that there is also
an important role for these large companies in many
publications by Schumpeter. Speciﬁcally the ‘older’
Schumpeter (1942) pictures a world of ‘modern,
trustiﬁed capitalism’ where large, science-based com-
panies dominate the innovative environment and where
innovation has become routinized in large research
laboratories and R&D departments. It is this particular
perspective on the role of large, established companies
that has for a long period, during the 1950s, 1960s,
and 1970s, dominated the understanding of the role of
1 As noted by one of the referees, it is important to mention here that
not all aspects of Schumpeterian theory hold when analyzing the phar-
maceutical biotechnology industry. According to Schumpeter (1934)
theentranceofentrepreneurialﬁrmsintoanexistingindustrygenerally
leads to a ’wave of creative destruction’ where established companies
are driven out of the industry. As new entrants to the pharmaceutical
industry were facing severe difﬁculties, i.e. a shortage of ﬁnance and
a lack of the complementary assets required to successfully commer-
cialize biotechnology, these ﬁrms did not replace the important role
played by established pharmaceutical companies.N. Roijakkers, J. Hagedoorn / Research Policy 35 (2006) 431–446 443
large companies as the main source of innovation (see
Kamien and Schwartz, 1982; Scherer, 1984).
In the combined biotechnology and pharmaceuti-
cal industry, the role of established companies is most
clearlyfoundinthedominantrolethattheseﬁrmsplayin
the more traditional pharmaceutical sub-sectors (Arora
and Gambardella, 1990). Large ﬁrms with their exten-
sive R&D activities and their long-term experience with
time-consuming clinical trials have come to dominate
the innovation process in the traditional pharmaceutical
industry.Thisdominanceisbasedontheirleadingrolein
incremental innovation, exploiting their current organic
chemical knowledge base, and their ability to expand
existing portfolios of pharmaceutical products.
Based on the literature discussed in the above, one
couldexpectthatthecentralroleofsmall,newlyfounded
biotechnology ﬁrms in research networks, as stressed
in the early work of Schumpeter, is likely to be most
obvious during the 1980s when many of these new
companiesintroducedmajorscientiﬁcandtechnological
breakthroughs in the pharmaceutical industry. However,
as the ﬁeld of pharmaceutical biotechnology has gradu-
ally matured, entrepreneurial biotechnology companies
could have become less important for inter-ﬁrm R&D
partnering while established ﬁrms may have become
more dominant. This more dominant role for large,
science-basedﬁrmsinamoreroutinizedinnovativeenvi-
ronment is particularly stressed in the later writings of
Schumpeter. In the following, we will see to what extent
new ﬁrms and/or established companies play an impor-
tant role in research networks in the pharmaceutical
biotechnology industry.
During the early years, from 1975 to 1979, the list-
ing of top 10 R&D partnering companies holds mostly
large, established pharmaceutical and chemical compa-
nies such as Ciba-Geigy, Sandoz, Johnson & Johnson,
and Bayer. Only the US-based ﬁrms Genentech and
Genex are small, newly founded biotechnological com-
paniesofsomeimportance,intermsoftheirparticipation
in these partnerships (see Table 1). The research net-
work for this period (see Fig. 3) shows a number of
isolated research clusters mostly centered around the
large, established pharmaceutical ﬁrms that we ﬁnd in
the ﬁrst column of Table 1. Particularly, there are ﬁve
multiple partner clusters and ﬁve dyadic partnerships,
involving mostly these large ﬁrms.
During the period 1980–1984, the number of large,
established pharmaceutical ﬁrms and chemical compa-
nies in the top ranking, such as Johnson & Johnson and
Ciba-Geigy, has decreased substantially (see Table 1).
During these years, the top of the list covers mainly
small,newlyfounded,biotechnologicalcompanies,such
as Genentech, Biogen, Genex, and Amgen, all from the
USA. For the most part, these biotechnological compa-
nies play an important ’bridging’ role in the sense that
they form crucial links between networks surrounding
pharmaceutical ﬁrms that otherwise would not be con-
nected. Some clear examples of this important ’bridg-
ing’ function are: Genex acts as a ’bridge’ between a
number of large companies, such as Bristol-Myers and
Pharmacia, and the large ﬁrms that are part of the net-
workaroundGenentech,i.e.RocheandBaxter-Travenol
Labs; Amgen serves as an important ’bridge’ between
the Genentech network and large companies, such as
Johnson & Johnson and Abbott Labs. Apart from the
increased overall density, there is another interesting
aspect of the network plot for this period, found in the
dense cluster around Genentech at the right-hand side of
Fig.4thatischaracterizedbymanyrepeatedties.Ingen-
eral, the overall network shows a fairly large number of
these multi-partner clusters, with relatively few isolated
partnerships.
The patterns that we observe for the period
1980–1984 become somewhat different when studying
thenextperiod,i.e.theyearsfrom1985to1989.Thetop
of the list is still headed by smaller biotechnology com-
panies, such as US-based Chiron, Biogen, and Genen-
tech,eachhavingmorethan10R&Dpartnershipsduring
theseyears(seeTable1).Asweobservedintheprevious
period, these small biotechnology companies, e.g. Chi-
ronandBiogen,serveasimportantconnectionsbetween
distantpartsofthenetwork.Biogen,forexample,formsa
’bridge’ between the network surrounding Merck (left-
hand side of the MDS plot in Fig. 5) and the network
around SmithKline Beckman (right-hand side of the ﬁg-
ure). If we examine Fig. 5 more closely, we see that
the biotechnological ﬁrm Genentech is still embedded
in a denser cluster structure involving quite a large num-
ber of research partners with which this company has
engagedinlonger-term,repeatedpartnershipsduringthe
second half of the 1980s. However, Table 1 also signals
the beginning of a new development where large, estab-
lished pharmaceutical companies, such as SmithKline
BeckmanandJohnson&Johnson,aresteadilybecoming
more important again. Interestingly, this ﬁnding coin-
cides with our ﬁnding that in the second half of the
1980s there is a strong increase in the use of joint R&D
agreements as opposed to research contracts. This also
indicates the growing role of importance for large ﬁrms
in biotechnological research and the networks conduct-
ing such research. In general, the network of inter-ﬁrm
partnerships has become quite complex with a relatively
largenumberofnodalplayersamidstmanyclusters,such
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Sandoz, Hoechst, Ciba-Geigy, Celltech, and many other
companies (see also Fig. 5).
The increasingly important role played by large,
established pharmaceutical and chemical ﬁrms in
biotechnological R&D networks becomes even more
obvious when we examine the list of most intensely
cooperating companies for the period 1990–1994 (see
Table 1). Most of the established companies showing
up in this listing, i.e. Ciba-Geigy, Merck, Glaxo, Eli
Lilly, SmithKline Beecham, and American Home Prod-
ucts, have formed at least 10 R&D partnerships with
pharmaceuticalbiotechnologypartnersduringtheperiod
1990–1994. Furthermore, their increasing importance
becomes clear when looking at the R&D network in
Fig.6whereanumberofthesecompanies,suchasCiba-
Geigy and Merck, have become star network players
that are embedded in dense local research clusters with
many participating partners and numerous longer-term,
repeated ties. Also, most of these important network
players are now directly connected to the research net-
works of other large players and do not rely so much
anymore on small ﬁrms fulﬁlling important ’bridging’
roles. Ciba-Geigy, for example, is directly linked to the
dense networks around a number of large companies,
such as Pﬁzer and SmithKline Beecham. In contrast to
our ﬁnding in the previous period that a small num-
ber of biotechnological research ﬁrms still held strong
positions in the rank order of leading network partici-
pants, this group of companies no longer plays a role
of importance during the current period. Chiron, now
a medium-sized biotechnological ﬁrm and one of the
few companies that has succeeded in marketing new,
biotechnological drugs, obviously forms the exception
(see also Table 1). Being the only biotechnological ﬁrm
in the listing of nodal players, this company, with its 13
R&D partnerships, holds an important position in the
research network that was in existence during the period
1990–1994.
For the ﬁnal years of our period of analysis
(1995–1999),Table1showsalistofthemostcentralnet-
work players that only covers a number of well-known,
established pharmaceutical companies, such as Roche,
SmithKline Beecham, and Pﬁzer, and a group of more
chemically oriented ﬁrms that also have some business
in pharmaceuticals, such as Rhˆ one-Poulenc, Hoechst,
and Bayer. In congruence with the very dense network
structure visualized in Fig. 7, these companies have
entered into very large numbers of joint R&D agree-
ments during the second half of the 1990s. The Roche
group, which is based in Switzerland, for example, has
formed a large number of 41 R&D partnerships dur-
ing this period (see also Table 1). The top right-hand
side of Fig. 7 shows that Roche is one of the star play-
ers we referred to previously as being embedded in a
very dense local network cluster where many cluster
members are connected to Roche through more than
one tie. If we take a closer look at Fig. 7, we observe
that the majority of these star players located at the
right-handsideoftheﬁgureareamongstthelarge,estab-
lished ﬁrms found in the last column of Table 1, such
as SmithKline Beecham, Pﬁzer, Bristol-Myers Squibb,
Glaxo Wellcome, Hoechst, Bayer, AstraZeneca, Mon-
santo, and Novartis. Interestingly, the relatively isolated
position of these companies and their research clusters
at the right-hand side of Fig. 7 indicates that neither the
star players nor their direct partners have many links to
the larger part of the network located at the center of
Fig. 7. The formation of these research clusters seems
to be a characteristic of both sparse R&D networks (see
Fig. 3) and very dense networks (see Fig. 7), and much
lesssoofnetworksofmediumdensity.Aﬁnalinteresting
characteristic of the particular R&D network shown in
Fig. 7 is that the central players embedded in the dense,
isolated clusters at the right-hand side of the ﬁgure, e.g.
Roche and SmithKline Beecham, are directly connected
to the centers of other clusters, e.g. the ones surrounding
Bristol-Myers Squibb, AstraZeneca, and Hoechst. The
decreasing’bridging’functionofbiotechnologicalcom-
panies is even more apparent in this ﬁgure than it was in
Fig. 6.
4. Conclusions
Our analysis of these longitudinal data clearly sug-
gestsanoverallgrowthinthenumberofannually,newly
established inter-ﬁrm R&D partnerships in the pharma-
ceutical biotechnology industry since the 1980s. The
particular growth pattern, found in the data, is explained
byreferringtoimportantdevelopmentsintheavailability
of venture capital and the inﬂuence of large-scale, gov-
ernmentalresearchprojects,suchastheHumanGenome
Program.Overtime,companiesactiveinpharmaceutical
biotechnology consistently prefer contractual partner-
ships, i.e. research contracts and joint R&D agreements,
to equity-based alliances. The growth in R&D part-
nerships in pharmaceutical biotechnology is primarily
causedbytheneedoflargepharmaceuticalcompaniesto
accessarecentexplosionofbiotechnologicalknowledge
and a diversity of new research ideas and approaches.
In congruence with ‘early’ Schumpeterian views, our
ﬁndings are highly indicative of the signiﬁcant role
played by small, entrepreneurial biotechnological com-
panies in research networks, particularly, during the
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the pharmaceutical industry. During that period, small
entrepreneurialbiotechnologicalcompaniesdidnotonly
play a crucial role in the emergence of inter-ﬁrm net-
works, they also formed important bridges between sub-
networks surrounding large pharmaceutical companies.
The 1990s, however, seem to demonstrate a decreas-
ing importance of these small, newly founded compa-
nies in inter-ﬁrm R&D partnering if compared to the
role of large, established pharmaceutical and chemical
ﬁrms. Also, the role of these small companies as bridges
between major sub-networks became less prominent.
During these more recent years, large companies have
developed into more dominant, star players with mul-
tiple partnerships while occupying a nodal position in
the pharmaceutical biotechnology inter-ﬁrm R&D net-
work. This latter development is clearly more in line
with expectations regarding inter-ﬁrm networks that are
inspired by the later writings of Schumpeter.
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Appendix A. Data and sample
For our analysis, we make use of data on inter-
ﬁrm R&D partnerships. These data are taken from
the MERIT-Cooperative Agreements and Technology
Indicators (CATI) information system (see Hagedoorn,
1993). This databank contains information on nearly
10,000 cooperative agreements in various sectors, rang-
ingfromhightechnologysectorssuchasITandbiotech-
nology to less technology intensive sectors, such as
chemicals and heavy electrical equipment. Cooperative
agreementsaredeﬁnedasmutualinterestsbetweeninde-
pendent industrial partners that are not linked through
majority ownership. In the CATI database, only those
agreementsarebeingrecordedthatinvolveeitheratech-
nologytransferorsomeformofjointlyundertakenR&D.
Information is also collected on joint ventures in which
new technology is received from at least one of the part-
ners, or on joint ventures having some R&D program.
Other types of agreements such as production and mar-
keting alliances are not included. Agreements formed
betweencompaniesandgovernmentaloracademicinsti-
tutions are generally not included in the database unless
they involve at least two commercial companies.
The current paper focuses on those partnerships that
were established in the period 1975–1999. In the CATI
databankatotalof1469globalR&Dagreementsinvolv-
ing 890 biotechnological companies and pharmaceuti-
cal ﬁrms were recorded during this time frame. Our
data include equity agreements, which comprise joint
ventures and minority holdings, as well as non-equity
alliancesthatconsistofjointR&DagreementsandR&D
contracts. The data excludes agreements that are estab-
lished within the context of national and international,
government sponsored, R&D cost-sharing programs.
For our purpose, the most relevant information for each
partnership is the number of companies involved, their
names as well as the year in which the agreement was
established.
Appendix B. Najojo
To facilitate our analysis and visualize the different
research partnering networks that have come into exis-
tence during each of the 5-year sub-periods examined in
thispaper,wemakeuseofourownnetworkvisualization
software tool Najojo. As existing visualization software
hasseriousdifﬁcultiesinhandlingthekindoflarge-sized
research networks that we study, we came up with the
ideatodevelopthesoftwaretoolNajojo.Thistool,which
is capable of visualizing large, dense networks involv-
ing more than 500 companies, was ultimately created by
Johan Willekens.
There are two separate input (text) ﬁles underlying
the generation of networks in Najojo: one ﬁle holding
the MDS coordinates for each of the individual compa-
nies participating in the network and one ﬁle holding
all unique company pairs and their numbers of research
partnerships. On the basis of the ﬁrst input ﬁle, Najojo
determines whether the particular network will be visu-
alized in landscape (see for example Figs. 3–5 and 7)o r
portrait orientation (see Fig. 6). As a second step in the
visualization process, the tool divides up the landscape-
or portrait-oriented space in an X number of points.
The ﬁrm coordinates held by the ﬁrst input ﬁle are then
mapped onto these points and visualized as dots. While
creating this scatter plot, the program makes sure that
the relations between dots are held constant and that
dots belonging to different companies do not overlap.
Thirdly, company labels are placed with the dots in such
a way that they do not overlap with other labels or dots.
Najojo variably determines the font size of company
labels depending on network density and the number
of companies participating in the network.446 N. Roijakkers, J. Hagedoorn / Research Policy 35 (2006) 431–446
Fourthly, on the basis of the second input ﬁle, Najojo
visualizes the total number of research partnerships
entered into by all unique company pairs making up the
network. The tool ﬁrst identiﬁes both research partners,
i.e. the beginning and ending dots, and subsequently
draws polybezier lines between these dots, making sure
thattheselinesdonotcrossdotsbelongingtocompanies
that are not part of the partnership. The type of line (dot-
ted, solid, and thick solid) that is drawn for each alliance
intensity can be determined by the user.
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